Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219817
Status:
COMPLETED
Last Update Posted:
2013-09-02
First Post:
2005-09-12
Brief Title:
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
Sponsor:
Helsinn Therapeutics US Inc
Organization:
Helsinn Therapeutics US Inc
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients Activation of Ghrelin receptors have been demonstrated to stimulate appetite RC-1291 HCl by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None